Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Mutation

Mutation

CIViC ID: 208 · Gene: NRAS

Variant Summary

HGVS: —
Variant Type(s): gain_of_function_variant,transcript_variant
Evidence Items: 19

Evidence Level Distribution

Level A: 1Level B: 12Level C: 1Level D: 5

Evidence Items

Showing CIViC evidence rows where gene = NRAS and variant = Mutation.

Level	Type	Direction	Significance	Disease	Drugs	Rating
B	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Binimetinib	5
D	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Omipalisib	4
B	Prognostic	Supports		Multiple Myeloma		4
A	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab,Panitumumab	4
B	Predictive	Does Not Support	Sensitivity/Response	Solid Tumor	Binimetinib	3
D	Predictive	Supports	Sensitivity/Response	Cancer	Metformin,Trametinib	3
D	Predictive	Supports	Sensitivity/Response	Melanoma	Binimetinib	3
B	Prognostic	Supports	Poor Outcome	Colorectal Cancer		3
B	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Binimetinib,Ribociclib	3
B	Prognostic	Does Not Support		Acute Myeloid Leukemia		3
B	Prognostic	Supports	Poor Outcome	Melanoma		3
B	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib,Docetaxel	2
B	Predictive	Does Not Support	Sensitivity/Response	Melanoma	Trametinib	2
B	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Binimetinib	2
D	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	2
B	Predictive	Supports	Resistance	Colorectal Cancer	Chemotherapy,Cetuximab	2
B	Predictive	Supports	Resistance	Melanoma	Vemurafenib,Dabrafenib	2
C	Predictive	Does Not Support	Resistance	Melanoma	MEK Inhibitor RO4987655	2
D	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Amuvatinib	1